Skip to main content

Table 2 Univariate analysis of COX2 expression (ID-Score)

From: COX2 expression is associated with proliferation and tumor extension in vestibular schwannoma but is not influenced by acetylsalicylic acid intake

  n (%) Mean (95%CI) p-value (ANOVA)
Age (years)
  < 56.19 777 (74) 1.83 (1.78–1.89) <  0.0001*
  > =56.19 271 (26) 2.07 (1.99–2.16)  
MIB1 (% expression)
  < 1.03 319 (30) 1.68 (1.60–1.76) < 0.0001*
  > =1.03 729 (70) 1.99 (1.94–2.04)  
Gender
 Female 544 (52) 1.95 (1.89–2.01) 0.0179*
 Male 504 (48) 1.84 (1.78–1.90)  
Primary/Recurrence
 Primary 992 (95) 1.89 (1.84–1.94) 0.7074
 Recurrence 56 (5) 1.93 (1.74–2.13)  
Subtype
 Sporadic VS 933 (89) 1.92 (1.88–1.97) 0.0005*
 NF2 VS 115 (11) 1.67 (1.54–1.81)  
Prior Treatment
 None 1011 (96) 1.88 (1.84–1.93) 0.0009*
 Radiotherapy 37 (4) 2.29 (2.05–2.53)  
Hannover Classification
 T1 49 (5) 1.17 (0.98–1.37) < 0.0001*
 T2 220 (21) 1.62 (1.53–1.71)  
 T3 402 (38) 1.92 (1.85–1.99)  
 T4 377 (36) 2.12 (2.05–2.20)  
 T1/2 269 (26) 1.54 (1.45–1.62) < 0.0001*
 T3/4 779 (74) 2.02 (1.97–2.07)  
Medication
 ASA 49 (5) 2.03 (1.82–2.23) 0.2046
 No ASA 999 (95) 1.89 (1.84–1.94)  
 NSAID 77 (7) 1.93 (1.76–2.09) 0.6887
 No NSAID 971 (93) 1.89 (1.85–1.94)  
 COX2-Inhibitor 2 (0.2) 2.25 (1.23–3.27) 0.4967
 No COX-Inhibitor 1046 (99) 1.90 (1.85–1.94)  
 Cortisol 27 (3) 2.02 (1.74–2.30) 0.3821
 No Cortisol 1021 (97) 1.89 (1.85–1.94)  
 Immunosuppressants (incl. cortisol) 32 (3) 2.00 (1.74–2.26) 0.4183
 No immunosuppressants 1016 (97) 1.89 (1.85–1.94)  
\